| o9dykainyu | Datum: Subota, 18-Jan-2014, 4:46 AM | Poruka # 1 |
|
Generalissimo
Grupa: Users
Poruka: 3207
Reputacija: 0
Status: Trenutno nije na sajtu
| Amarin Announces Additional Data From Clinical Trials
Possess in my opinion that due to the complexities related to a partnership deal that BP would want to take advantage of the ball rolling earlier than later. However Amarin's choosing JP Morgan has them seeing any collaboration occurring surrounding the Dec PDUFA date and even <a href=http://fenntaler.nl/cd/agu.html>http://fenntaler.nl/cd/agu.html</a> even later. I often only hope that Amarin is playing possum or "hard to get" here. This stock price leaves shareholders vulnerable should NCE not come through. The shorts have an industry day using this. I've held a lot of shares since prior to the MARINE trial results. Prepare yourself for some must be some positive movement inside the stock price and institutional support soon to stay the commitment. Time is money for any one.
Hi, first JPM wouldn't say no buyout/partnership this coming year, i was told that improbable until even closer <a href=http://fotovakprint.nl/images/ugg.html>http://fotovakprint.nl/images/ugg.html</a> or after Anchor approval. I've truly alluded to this from the time of I blew telephone call that big pharma would enter before anchor sNDA recently. And also observing reports of PFE and AZN making <a href=http://fenntaler.nl/cd/aj.html>ジョーダン スニーカー</a> consulting requests for expert matter in your cardiovascular space. Even as it is often unrelated, I am inclined to believe some formal homework could very well be underway with Amarin. Just something to watch out.
Steve I appreciate the necessary commentary, articles, research and due research. It's the sole reason I'm here and studied all you write. On the other hand, a handful of a foreign language is hints that you will be guessing which isn't considerably more when compared to the everybody else. " I have been observing reports." What do i mean? Is usually that 1st,2nd,3rd or 4th hand knowledge? "I Usually tend to believe some formal required groundwork Might well be underway." ?This language highlights the current disadvantage to trying out Amarin. Specifically, having no factual knowledge the amount is absolutely doing as respects the commercialization direction Amarin will administer. Joe Z's style of management has produced endless speculation and subsequently the proportion price has suffered tremendously and in conjunction with it, shareholders. buyout hopes are generally dashed repeatedly. I know this is certainly all part of the experience but Joe Z's MO has generated too little institutional support combined with retail support. My suggestion to your account will be to not fall under that trap yourself. Once you learn an element that can help everyone, of course share it. Otherwise it is advisable to keep clear of comment. Any time a concrete plan for commercialization of your ANCHOR indication isn't ready shortly( or even articulated) after approval on the ANCHOR sNDA, it'll indicate to investors that management is struggling and adrift.
[url=http://www.wmarketnyc.com/aj.html]エアジョーダン激安[/url]
|
| |
| |
